SCNI
Scinai Immunotherapeutics Ltd. (SCNI) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
R&D intensity of 1.32% of revenue suggests limited disclosed environmental innovation spending versus peers with heavier clean-technology or process-decarbonization investment.
Negative gross profit margin indicates weaker operating efficiency, which can constrain funding for environmental compliance and transition initiatives relative to better-capitalized peers.
Low debt-to-equity of 0.31 and net cash position reduce balance-sheet pressure, supporting flexibility to absorb environmental capex better than more leveraged peers.
No provided evidence of emissions, energy, water, or waste disclosure limits confidence, leaving environmental positioning broadly average versus peers with more transparent reporting.
Social
Stock-based compensation at 2.28% of revenue is modest, implying less dilution pressure and potentially better alignment than peers with heavier equity-based pay practices.
No provided workforce, safety, turnover, or customer-impact metrics prevents evidence of stronger social management, keeping the profile near peer-average.
Negative gross margin can indirectly pressure staffing stability and training budgets, which may weaken social execution versus peers with stronger operating buffers.
The absence of controversy data avoids a clear social penalty, but limited disclosure still trails peers that report more complete human-capital metrics.
Governance
Debt-to-equity of 0.31 and net cash indicate conservative capital structure, which generally reduces creditor pressure and supports governance flexibility versus leveraged peers.
Stock-based compensation at 2.28% of revenue suggests restrained equity dilution, a positive governance signal relative to peers with more aggressive pay practices.
Negative gross margin raises concern about operational oversight and capital allocation discipline, but it is not by itself a structural governance weakness versus peers.
No filing-based evidence of board independence, audit quality, or shareholder-rights issues limits conviction, leaving governance slightly above average but not leading.
Overall Score
SCNI appears modestly better than peers on capital discipline and balance-sheet conservatism, but limited ESG disclosure and weak operating efficiency cap its relative positioning.
Score Driver: Conservative Leverage And Restrained Equity Compensation
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Scinai Immunotherapeutics Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
